Recursion Pharmaceuticals, Inc. (RXRX): Depreciation & Amortization
$83.70M
Year ended 2025-12-31
$78.36M
Trailing 12 months to 2026-06-30
+92.4%
3-year compound annual growth
+84.2%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $83.70M | +129.4% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $36.49M | +49.6% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $24.40M | +107.6% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $11.76M | +39.9% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $8.40M | +113.2% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $3.94M | +58.4% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $2.49M | n/a | 2022-03-23, From 2019-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $83.70M | +129.4% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $8.30M | +9.8% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $11.68M | -19.8% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $12.54M | -2.2% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $4.69M | +0.9% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $1.38M | -16.0% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $7.32M | +1.5% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $15.53M | -11.6% |
| Agenus Inc (AGEN) | 2025-12-31 | $10.00M | -25.1% |
Compare RXRX, AUTL, VIR, MGTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗